TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04050644
Drug: Preservative Free drop treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will use the preservative-free dexamethasone 0.1% 4 times a day in the first week after cataract surgery, 3 times a day in the second week, twice daily in the third week and once daily in the fourth week and diclofenac 0.1% eye drops 3 times daily for 1 day preoperatively and every 15 minutes in the hour before surgery and then 3 times a day for four weeks.
Study: NCT04050644
Drug: Preserved drop treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will use the preserved dexamethasone 0.1% 4 times a day in the first week after cataract surgery, 3 times a day in the second week, twice daily in the third week and once daily in the fourth week and diclofenac 0.1% eye drops 3 times daily for 1 day preoperatively and every 15 minutes in the hour before surgery and then 3 times a day for four weeks.
Study: NCT01443845
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-matched placebo, oral administration, once per day.
Study: NCT00561301
Drug: GemDOx
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine oxliplatin
Study: NCT03381703
Drug: YH12852
Approvals — FDA: no, EMA: no, PMDA: no
Description: YH12852 administration
Study: NCT02271854
Drug: Diclofenac sodium gel 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac sodium gel 1% four times daily (This study is a within-subject design i.e. active drug applied to one leg and placebo to the other leg at the same time. Therefore the study design is not a cross-over).
Study: NCT02271854
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel four times daily (This study is a within-subject design i.e. active drug applied to one leg and placebo to the other leg at the same time. Therefore the study design is not a cross-over).
Study: NCT00807144
Drug: Kidney transplant maintenance immunosuppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release Tacrolimus 1 to 20mg daily in a single am dose adjusted to trough drug levels 6-9ng/ml
Study: NCT00735072
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose based on current medications in regimen: 150mg PO BID for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens.
Study: NCT03923829
Drug: Zinc Sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: systemic administration of Zinc sulfate with scaling and root planing
Study: NCT03454529
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01456013
Drug: Standard Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care for patients at risk of CIN
Study: NCT03465527
Drug: PrednisoLONE 50 MG
Normalized name: prednisolone 50 MG
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone 50mg bid po or iv (equivalent dose of other steroid) for 5 days ± 2 days
Study: NCT02086097
Drug: Dexketoprofen trometamol
Normalized name: Dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25m of dexketoprofen (oral intake) every 8 hours
Study: NCT02086097
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg of Ibuprofen (Oral Intake) every 8 hours
Study: NCT02086097
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: INACTIVE SUGAR PILLS
Study: NCT00240149
Drug: Regular Insulin via Insulin-Glucose Algorithm
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02568644
Drug: Intravenous ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received intravenous ketoprofen (100mg).
Study: NCT00404573
Drug: RGH-188
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00729560
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily for 4 weeks
Study: NCT01511549
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:injection~Route of administration: intra-articular
Study: NCT01511549
Drug: SAR113945
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:injection~Route of administration: intra-articular
Study: NCT00634075
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The enrolled patients will be randomized to receive either supplementation of fish oil-based lipid emulsion (10 % Omegaven) as group 1 or placebo (0.9% Normal Saline) as group 2 via a central venous catheter within 24 hours after ICU admission, 100 ml daily for 5 days, respectively.
Study: NCT01972724
Drug: Sulfonylurea
Normalized name: Sulfonylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfonylurea as prescribed in clinical practice
Study: NCT01721434
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Similar coloured placebo
Study: NCT03186079
Drug: Fiberform
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiberform is a low-phytate wheat fibre which can increase the gastrointestinal motility.
Study: NCT01408732
Drug: Sclerotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% Sodium tetradecyl sulfate (STS) is mixed with air at a ratio of 4 parts air to 1 part STS for injection into the affected vessels in the nose. Topical anesthetic is applied to the nasal mucosa prior to injections. Once the mixture is ready for injection, the needle is placed into the vessel, in a submucosal fashion, penetrating 1-2 mm, and very small quantities of foam are injected The amount of foam injected into each lesion varies between 0.1 cc to 0.25 cc. Individual injection amounts vary between lesions, patients and treatment sessions. No more than a total of 3 ml of solution is used in each session. During each session, several lesions can be treated, but the total amount of STS used does not exceed 3 cc.
Study: NCT00749749
Drug: ON-Q PainBuster Post-op Pain relief System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL/hr per catheter of 0.25% bupivacaine (12.5 mg) for 72 hours(total dose 360 mL \[900 mg\])
Study: NCT00002919
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002919
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05780229
Drug: Pain-Relief Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the reverse prosthesis procedure and arthroscopic decompression surgery, the pain-relief medication plan is a standard regimen for all patients, which can be modified as needed. This plan is based on 50mg of dexketoprofeno, 1g of paracetamol, and 100mg of tramadol.
Study: NCT01897259
Drug: Placebo Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the placebo group will recieve placebo injections (1cc 1% lidocaine and 1cc normal saline).
Study: NCT01897259
Drug: Corticosteroid Injections
Normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the corticosteroid group will recieve corticosteroid injections (1 cc Kenalog 10 mg). They will also recieve anesthetic of 1 ml 1% lidocaine.
Study: NCT03598140
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once (Group 1) or daily for 2 weeks (Group 2)
Study: NCT01845428
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After collecting baseline plasma samples, participants will receive pravastatin 20mg daily. After 6 weeks, we will collect samples and safety data. Subsequent statin therapy will be at the discretion of the treating physician.
Study: NCT00648349
Drug: Aciphex® Delayed-Release Tablets 20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg, single dose fasting
Study: NCT00681525
Drug: ABT-335
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: One ABT-335 135 mg capsule QD for 10 days
Study: NCT02658240
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg epinephrine
Study: NCT02918279
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered once daily subcutaneously (s.c., under the skin)
Study: NCT03860532
Drug: HMPL-011 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible subjects will recieve 1200 mg HMPL-011 tablets under fed and diet circumstance.
Study: NCT03860532
Drug: HMPL-011 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible subjects will recieve 1200 mg HMPL-011 capsules under fed and diet circumstance.
Study: NCT02432690
Drug: BBI503
Approvals — FDA: no, EMA: no, PMDA: no
Description: BBI503 will be administered orally, once daily. Dosing will begin at 200 mg once daily, preferably at bedtime and 2 hours after a meal. Dose modification in case of adverse events is allowed according to the schedule below; Full dose: 200 mg daily, Modification Level-1: 100 mg daily, Modification Level-2: 50 mg daily.
Study: NCT00875160
Drug: AT2101
Approvals — FDA: no, EMA: no, PMDA: no
Description: 225mg (nine 25mg capsules total dose) to be taken by mouth every day for 9 days (Study Days 1, 3-10)
Study: NCT04688801
Drug: Chemotherapy Drugs, Cancer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy± Radiotherapy after surgery
Study: NCT01135511
Drug: CP-690,550 Eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic topical solution, medium dose, dosed once/day, 8 weeks
Study: NCT04432324
Drug: Standard Medical Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMT
Study: NCT04679571
Drug: Standard Medical Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Medical Treatment- Salt-restriction, diuretics with large volume paracentesis These patients will be put on low sodium diet (2 g/day) and will be given a combination of loop diuretic (furosemide 40-160 mg/day) and a distal acting diuretic (spironolactone 100-400 mg/day) with dose escalation by one step at a time with monitoring for side-effects. Large volume paracentesis (LVP) will be performed along with intravenous albumin (8 g/L ascites removed) as required with record of the frequency of taps.~Follow up: 2 week, 4 weeks then every 3 months for 1 year.
Study: NCT01641224
Drug: Ledebouriella Root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ledebouriella Root (\~10g)
Study: NCT03583125
Drug: EOC317
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet(s) PO
Study: NCT01641224
Drug: Fingered citron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingered citron (\~10g)
Study: NCT01641224
Drug: Tuckahoe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tuckahoe (15g)
Study: NCT01641224
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is blindly given to patients.
Study: NCT02329860
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00534300
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion, 100 mL, 25mL/h
Study: NCT03151772
Drug: Disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg disulfiram two times daily and 2,5 mg copper once daily taken preoperatively
Study: NCT04102696
Drug: Aromatherapy
Normalized name: ISOPROPYL ALCOHOL 75 mL in 100 mL TOPICAL CLOTH [Roots Aromatherapy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free aromatherapy (70% menthol and 30% propanediol) will be provided for 6 months. All participants will receive the standard inhalation method training before hospital discharge.~The aromatherapy will be given twice daily, one treatment in the morning and one in the evening. At each treatment, 4 deep steady inhalations will be performed, and 10 seconds per inhalation is optimal.
Study: NCT04102696
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free placebo (10% menthol and 90% propanediol) will be provided for 6 months. The specific method is the same as aromatherapy.
Study: NCT04135989
Drug: Standard DAPT duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of dual antiplatelet therapy for 12 months.
Study: NCT01490086
Drug: RP5063
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily
Study: NCT01490086
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily
Study: NCT03418805
Drug: Ibuprofen CR Tablets 600 mg
Normalized name: ibuprofen Chewable Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of the investigational product:~Single oral dose of IBUCR, followed by 28 and 32 hours after the dose administration for fasted and fed studies, respectively
Study: NCT02235272
Drug: XG-102
Normalized name: Ninjacof XG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of XG-102 versus placebo sub-conjunctival injection efficacy
Study: NCT02235272
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparison of XG-102 versus placebo sub-conjunctival injection efficacy
Study: NCT04372979
Drug: Transfusion of SARS-CoV-2 Convalescent Plasma.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 Convalescent Plasma units of 200-230mL each, inactivated by amotosalen.
Study: NCT04372979
Drug: Transfusion of standard Plasma.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 Standard Plasma units of 200-230mL each, inactivated by amotosalen.
Study: NCT00909883
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection
Study: NCT02182999
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: The catheter is connected to the perfusor line filled with saline 0.9% to allow continuous wound infiltration at a rate of 2 ml/h for 24 hours.
Study: NCT00498368
Drug: ACE/ARB
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors and /or ARBs will be used to achieve a blood pressure goal of \<130/80 millimeters of mercury (mmHg). Patients not attaining the target blood pressure with an ACE inhibitor or ARB alone should be treated with the combination of ACE inhibitor (ACEi) + ARB
Study: NCT03149991
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of placebo which matches brexpiprazole in size and number of tablets per dose
Study: NCT00648726
Drug: cefuroxime plus erythromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous cefuroxime 1.5 g twice daily for 4 +/-1 days, followed by oral cefuroxime 0.5 g twice daily for a total duration of 9 +/-1 days plus erythromycin ethylsuccinate 0.5 g twice daily, which was given for a total duration of 14 days for subjects with suspected pneumonia due to atypical pathogens
Study: NCT00648726
Drug: azithromycin (Zithromax)
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous azithromycin 500 mg once daily for 4 +/-1 days, followed by oral azithromycin 500 mg once daily for a total duration of 9 +/-1 days
Study: NCT01224015
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
Study: NCT02092506
Drug: 10 day triple therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 day triple therapy
Study: NCT02092506
Drug: 10 day sequential therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 day sequential therapy
Study: NCT02092506
Drug: 10 day concomitant therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 day concomitant therapy
Study: NCT01962909
Drug: PTP-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 1 is 10mCi (50ug of peptide)
Study: NCT01895075
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml normal saline by inhalation
Study: NCT00001832
Drug: gp100:209-217 (210M)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gp100 = gp100:209-217(210M) peptide - 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus gp100:209-217(210M) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.~MART-1 = MART-1:26-35(27L) peptide- 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus MART-1:26-35(27L) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.
Study: NCT01501162
Drug: hepatitis, alcohol, probiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days of probiotics (1500 mg/day)
Study: NCT01501162
Drug: alcohol, hepatitis, Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebos of the same shape and size were manufactured at Pharmaceutical Corporation.
Study: NCT02108210
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02853565
Drug: CAN008
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose escalation in the phase I study including 200mg in the first cohort and 400mg in the second cohort to Recommended for Phase 2 Dose (RP2D)
Study: NCT00001832
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2x30 mg/kg, 2x60 mg/kg intravenous
Study: NCT01394055
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo volume subcutaneously once
Study: NCT00474773
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01785290
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium Chloride 0.9%
Study: NCT03220425
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01832480
Drug: MTZ 500 mg twice daily x 7 days
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MTZ 500 mg twice daily x 7 days
Study: NCT01832480
Drug: MTZ 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTZ 2 g
Study: NCT02591836
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00906828
Drug: levodopa/carbidopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: intestinal gel, continuous infusion (daytime or 24-hour)
Study: NCT00092885
Drug: Comparator: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00731185
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01038011
Drug: drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00251576
Drug: A-Phase: tirofiban; Z-Phase simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00251576
Drug: Duration of Treatment: A-Phase: minimum suggested 48 hours, maximum suggested 108 hours. Z-Phase: 2 years
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00251576
Drug: Comparator: A-Phase: low molecular weight heparin, unfractionated heparin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00251576
Drug: Duration of Treatment: A-Phase: low molecular weight heparin, 2 to 8 days; unfractionated heparin, minium suggested 48 hours, maximum 108 hours
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00251576
Drug: Duration of Treatment: Z-Phase, 2 years.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04222686
Drug: Perindopril Arginine
Normalized name: Perindopril Arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Perindopril tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
Study: NCT00372294
Drug: Clindamycin+Dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of Clindamycin+Dexamethasone
Study: NCT00102804
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV administration, q 21 days
Study: NCT00704184
Drug: Comparator: Pegylated-Interferon (Peg-IFN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peg-IFN 180 mcg once-weekly subcutaneous injection; duration of treatment: 48 weeks
Study: NCT00704184
Drug: Comparator: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to vaniprevir; duration of treatment: 28 days
Study: NCT04412668
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concentrate for solution for infusion
Study: NCT03954704
Drug: mFOLFOX6 Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimen of oxaliplatin, 5-fluorouracil \[5-FU\], and leucovorin
Study: NCT04137055
Drug: ZSP0678-10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZSP0678 tablet administered orally under fasted condition
Study: NCT01764464
Drug: Gralise®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 day titration (days 1-7 at 600 mg daily Gralise®; days 8-14 at 1200 mg daily Gralise®). 28 day maintenance (1800 mg daily Gralise®). 7 day taper (days 1-4 at 1200 mg daily Gralise®; days 5-7 at 600 mg daily Gralise®).
Study: NCT01764464
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 day titration (days 1-7 at 600 mg daily placebo; days 8-14 at 1200 mg daily placebo). 28 day maintenance (1800 mg daily placebo). 7 day taper (days 1-4 at 1200 mg daily placebo; days 5-7 at 600 mg daily placebo).
Study: NCT04137055
Drug: ZSP0678-30mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZSP0678 tablets administered orally under fasted condition
Study: NCT04137055
Drug: ZSP0678-120mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZSP0678 tablets administered orally under fasted condition
Study: NCT04137055
Drug: ZSP0678-180mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZSP0678 tablets administered orally under fasted condition
Study: NCT04137055
Drug: ZSP0678-240mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZSP0678 tablets administered orally under fasted condition
Study: NCT04137055
Drug: ZSP0678-320mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZSP0678 tablets administered orally under fasted condition
Study: NCT04137055
Drug: ZSP0678
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZSP0678 tablets administered orally under fasted or fed condition
Study: NCT04137055
Drug: ZSP0678-Dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZSP0678 tablets administered orally once daily for 14 Days
Study: NCT04137055
Drug: ZSP0678-Dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZSP0678 tablets administered orally once daily for 14 Days